News

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against the myopia epidemic, which is expected to affect approximately 5 billion people worldwide by 2050.1

Space at the Euclid facility in Sterling, Virginia, has now been expanded over 40%. Additions include larger manufacturing space, quality assurance labs, offices, and engineering/R&D space.

“With the launch of our game-changing Euclid Max Ortho-K lens this year, we have entered a very exciting time at Euclid. But our steadfast commitment to innovation is not taking a break. We’ve just expanded our manufacturing space and employee resources for the second time in three years and continue to grow our leadership team for future expansion,” said Euclid Systems CEO, Joseph Boorady. “We’re pleased to welcome Greg Endicott and Mark Mercier, who bring decades of experience, innovation, and results in fast-paced healthcare environments. Their knowledge and leadership, as well as the brick-and-mortar expansion of our facilities, help fortify Euclid’s growth as a cutting-edge world leader in myopia management technologies.”

As Chief Information Officer (CIO), Greg Endicott will lead Euclid’s strategic technology program and drive business initiatives in collaboration with global business leaders, including exploration of emerging technologies and new strategies. Previously, Mr. Endicott had a leadership role at Baxter Bioscience and was inaugural CIO of two scientific research companies. New Senior Director of Operations is Mark Mercier, a transformation specialist with decades of experience in contact lens manufacturing at Bausch+Lomb. Mr. Mercier will drive efficient methodologies throughout Euclid’s manufacturing and fulfillment.

Additional information on Euclid’s state-of-the-art manufacturing facility, and what differentiates Euclid in the industry, may be viewed in the video presentation, “Euclid – Your Partner in Myopia Management”.

To learn more visit the link.

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …